10th January 2020
- 0 comments
Ori Biotech Ltd, an innovator in Cell and Gene Therapy (CGT) manufacturing, has successfully closed a $9.4M (£7M) seed round which will be used to bring their innovative manufacturing platform to market. The Ori platform will deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.
The investor syndicate is comprised of some of the UK’s leading venture investors including Amadeus Capital Partners, Delin Ventures, Kindred Capital and a London-based family office, alongside a group of angel investors who have supported the company since inception.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.